Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Plexiform neurofibromas (PN) represent the main cause of morbidity in patients affected by Neurofibromatosis Type 1 (NF1). Until recently, surgery has been the main treatment option in these patients, but it is burdened with a low efficacy rate and a high incidence of side effects as well as recurrence. In recent years, MEK inhibitors (MEKi) such as selumetinib and trametinib have shown great promise.
Methods: We retrospectively describe a single center cohort of NF1 patients affected by PN1 and treated with MEKi since 2019 to 2021. Patients recruited in the study were affected by PN that were not eligible to complete surgical excision, symptomatic or with major cosmetic deformation or functional neurological deficits.
Results: Most patients experienced improvement in clinical symptoms and quality of life, with reduction or stabilization of lesions. However, no complete response was achieved. The most common adverse effects involved the skin, affecting every patient. Importantly, no life-threatening adverse effects occurred.
Conclusions: In our experience, MEKi treatment has been shown to be both safe and effective in improving symptomatology and quality of life.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830579 | PMC |
| http://dx.doi.org/10.1177/10732748221144930 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pulmonary Langerhans cell histiocytosis (PLCH) is a rare diffuse lung disease that is strongly associated with cigarette smoking, with the BRAF V600E mutation identified in approximately half of all cases. In Japan, combination therapy with BRAF and MEK inhibitors has recently been approved as an alternative treatment option. We report the case of a 30-year-old woman diagnosed with BRAF V600E-mutant PLCH who was treated with dabrafenib in combination with trametinib.
View Article and Find Full Text PDFRedressing the Balance Against B Regulatory Cells: Novel Immunotherapeutic Target in Leishmaniasis.
Parasite Immunol
September 2025
Department of Zoology, Panjab University, Chandigarh, India.
Leishmania parasite adeptly evades the host's immune defences by infiltrating macrophages, exploiting apoptotic processes for further dissemination. Among the host's strategies to counter parasitic propagation, the pivotal role of B-cells, specifically B regulatory (Breg) cells, emerges. Recent evidence from in vitro and in vivo studies has thrust Breg cells into the spotlight, attributed to their IL-10 secretion and antigen presentation.
View Article and Find Full Text PDFTargeting pathological ERK1/2 signaling in cancer and beyond.
Trends Mol Med
September 2025
Institute of Pharmacology and Toxicology, University of Würzburg, 97078 Würzburg, Germany; Leibniz-Institut für Analytische Wissenschaften (ISAS) e.V., 44139 Dortmund, Germany. Electronic address:
Dysregulation of the RAF-MEK-ERK1/2 pathway is involved in the pathoetiology of many diseases. Its central role in cancer has led to the development of drugs targeting upstream receptors, RAS, and kinases in the extracellular signal-regulated kinase 1 (ERK1) and 2 (ERK2) signaling cascade. The use of these drugs in cancer therapy - together with ongoing monitoring of their effectiveness, evolving side-effects, and resistance mechanisms - has expanded our knowledge of both the physiological and pathological functions of ERK1/2 and could thus provide potential alternative therapeutic strategies.
View Article and Find Full Text PDFUnveiling anaphylatoxins: Pioneering cancer therapies through complement system insights.
Biochim Biophys Acta Rev Cancer
September 2025
Department of Neurosurgery, The First Hospital of China Medical University, Nanjing Street 155, Heping District, Shenyang 110001, PR China. Electronic address:
The complement system, a cornerstone of innate immunity, plays pivotal roles in both defense and pathology, particularly through its anaphylatoxins, C3a and C5a. These small peptides, generated during complement activation, not only mediate pro-inflammatory responses but also contribute to the progression of various cancers by modulating the tumor microenvironment (TME). Anaphylatoxins influence tumor cell proliferation, epithelial-mesenchymal transition, angiogenesis, immune suppression, and therapy resistance via key signaling pathways such as PI3K/AKT, MEK/ERK, and p38 MAPK.
View Article and Find Full Text PDFThe intrinsic ability of cancer cells to evade death underpins tumorigenesis, progression, metastasis and the survival of drug-tolerant persister (DTP) cells. Herein, we discovered that when activated, the small GTPase ARF6 plays a central role in tumor survival by facilitating expression of the BRAF oncoprotein. Tumor-specific deletion caused a significant reduction in BRAF protein and MAPK signaling and prevented rapid tumor progression.
View Article and Find Full Text PDF